433 results about "Hepatic disorders" patented technology

Disclosed is a diagnosis or treatment method which utilizes the content of a specific fatty acid in plasma as a marker that reflects the condition of NASH or NAFLD, or utilizes the above-mentioned content in combination with another test, another marker or the like.

The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and / or cardiometabolic disorders.

The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.

The present invention provides novel pyrazolines that are useful as cannabinoid receptor antagonists / inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.

The invention discloses the usage of interleukin-22 during the preparative medicine for treating hepatic diseases, in particular to the application of medicine in preparing to treat alcoholic liver diseases and nonalcoholic fatty liver diseases. The range of application of the interleukin-22 is enlarged, bringing comfort to hepatopath. The invention also discloses a process for preparing the recombinant human interleukin-22, and the recombinant human interleukin-22 is produced by employing the method with high expression level and low costs, providing the foundation of mass production and application of the interleukin-22.

The present invention comprises compositions comprising essential oils, ginsenosides, and polysaccharides. The present invention comprises methods comprising sequential solvent extraction and polymer absorbent purification to obtain fractions comprising essential oils, ginsenosides, and polysaccharides. The compositions of the present invention may be used in forms such as tablets, gel caps, or fast-dissolve tablets for use as dietary supplements or pharmaceutical compositions. The compositions of the present invention may be used for treatment of cardiovascular diseases, neurodegenerative diseases, inflammatory diseases, hepatic disorders, viral diseases, and cancer.

The invention relates to a selenium-rich and zinc-rich lepidium meyenii planting method and lepidium meyenii products. When the lepidium meyenii is planted at areas of different altitudes, selenium and zinc base fertilizer is applied or selenium and zinc leaf fertilizer is sprayed during the growing period, the lepidium meyenii rich in organic selenium and organic zinc is planted, and therefore the functions of the lepidium meyenii products are increased, and the cost of lepidium meyenii raw materials is reduced by more than ten times. The selenium-rich and zinc-rich lepidium meyenii and traditional Chinese medicinal materials are prepared respectively into selenium-rich and zinc-rich lepidium meyenii chewable tablets, selenium-rich and zinc-rich lepidium meyenii powder, selenium-rich and zinc-rich lepidium meyenii liquor, selenium-rich and zinc-rich lepidium meyenii oral liquid, selenium-rich and zinc-rich lepidium meyenii solid and liquid beverages, selenium-rich and zinc-rich lepidium meyenii (instant) tea, selenium-rich and zinc-rich lepidium meyenii (instant) coffee and selenium-rich and zinc-rich lepidium meyenii delicious herbal cuisine. The obvious cooperation complementation effect is produced, and the selenium-rich and zinc-rich lepidium meyenii products are wide in sharing crowd and suitable for industrial production. The lepidium meyenii products are used for rehabilitation of the tumor, the leukemia, the hepatopathy, the cardia-cerebrovascular disease, the urinary systemic disease, the diabetes mellitus and the blood pressure diseases. The lepidium meyenii products are health products for healthy people to keep healthy, beautify, lose weight, tonify Yang and nurse the climacteric syndrome.

The invention provides a method of detecting, monitoring, assessing and treating non-alcoholic fatty acid liver disease (NAFLD) and associated liver damage in a subject comprising measuring the amount of hepatocyte-derived circulating extracellular vesicles (EVs) and / or microparticle (MPs) in the bodily sample, or the expression level or activity of at least one biomarker expressed or detected in the EVs and / or MPs. The increased amount of EVs or MPs in the bodily sample and / or the increased expression or detection level of the biomarker of interest correlate with the degree or severity of NAFLD, NASH, liver fibrosis, or other associated liver damage, which can be associated with angiogenesis. Prevention and treatment of NAFLD, NASH, liver fibrosis or associated liver damage by reducing EVs or MPs, or targeting the biomarkers expressed in the EVs or MPs are also provided.

Phytoceutical composition for the prevention and treatment of hepatic disorders. A specific combination of extracts of plants is taught, as well as the principles for the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.

Phytoceutical composition for the prevention and treatment of hepatic disorders. A specific combination of extracts of plants is taught, as well as the principles for the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.

Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.

The present invention relates to a novel tissue culture system that provides for the long term culture of proliferating hepatocytes that retain hepatic function. Disclosed are methods and compositions for ex vivo culturing of hepatocytes and nonparenchymal cells on a matrix coated with a molecule that promotes cell adhesion, proliferation or survival, in the presence of growth factors, resulting in a long-term culture of proliferating hepatocytes that retain hepatic function. The co-culturing method results in the formation of matrix / hepatic cell clusters that may be mixed with a second structured or scaffold matrix that provides a three-dimensional structural support to form structures analogous to liver tissue counterparts. The hepatic cell culture system can be used to form bio-artificial livers through which a subjects blood is perfused. Alternatively, the novel hepatic cell culture system may be implanted into the body of a recipient host having a hepatic disorder. Such hepatic disorders, include, for example, cirrhosis of the liver, induced hepatitis, chronic hepatitis, primary sclerosing cholangitis and alpha1 antitrypsin deficiency.

The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention is related to methods of treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.

A Chinese medicine in the form of honeyed pills for treating chronic hepatism and hepatic fibrosis is prepared from 13 Chinese-medicinal materials including saffron, red sage root, astragalus root, Chinese angelica root, etc through cleaning, pulverizing, sieving, proportionally mixing, adding honey, pilling and Co-60 sterilizing. Its advantage is high curative effect up to 94%.

The invention provides directional puncture sampling equipment for treating hepatopathy. The problems of low positioning precision, low puncture efficiency, inaccurate positioning and inaccurate needle insertion depth in the prior art are solved. The equipment comprises a telescopic support which is connected with an upper fixed ring. A lower fixed ring is connected with the lower part of the upper fixed ring. An outer gear ring and an inner gear ring are rotationally arranged between the upper fixed ring and the lower fixed ring. A one-way wheel is coaxially mounted on the outer gear ring. Afirst gear is mounted on the lower fixed ring. A second gear is meshed beside the first gear. The second gear is meshed with the inner gear ring. A probe mounting groove is formed in the inner gear ring. A first stop block and a second stop block are rotationally arranged on the two sides of the probe mounting groove. An arc-shaped pressing plate is mounted in the probe mounting groove. An ultrasonic probe is mounted in the probe mounting groove. A puncture needle is mounted on the rear side of the one-way wheel. According to the invention, position conversion among the ultrasonic probe, a disinfection bottle, an anesthetic needle and the puncture needle can be achieved; and liver and puncture can be positioned more accurately.

The present invention relates to the prevention and treatment of injury and diseases to the liver, biliary tract, bile ducts, gall bladder and related hepatobiliary system. Specifically, the present invention relates to methods for decreasing the action of the RON receptor tyrosine kinase in liver physiology. More specifically, the present invention relates to the use of analogs and antagonists and antibodies for inhibiting the action of the RON receptor tyrosine kinase for the prevention and treatment of liver injury or damage in acute and chronic clinical conditions.

Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.

The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and / or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.

The invention relates to a curcumin injection comprises the complex of curcumin and macromolecular complexing agent of hydroxyl propyl beta-cyclodextrin having polyhydroxy, water-soluble medicinal findings for injection and / or freeze-drying excipient, the dosage form includes transfusion and freeze dried. The invention also provides the process for preparing the curcumin injection, which can be used in the treatment for cancer, leukemia, hepatic diseases and cranial vascular diseases.

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating hepatic disorders such as hepatocellular carcinoma and / or cirrhosis. A variety of informative biomarkers corresponding thereto, are provided, wherein alterations in expression relative to a control is correlated with the presence of a hepatic disorder, likelihood of survival from a hepatic disorder, and likelihood of recurrence of a hepatic disorder.

A Chinese medicine for preventing and treating hepatism, viral hepatitis, fatty liver and alcoholic liver is prepared from 19 Chinese-medicinal materials including tuckahoe, notoginseng, red sage root, dandelion herb, etc. Its preparing process is also disclosed.

The invention relates to the field of polypeptide drugs, and in particular relates to polypeptide against hepatitis B virus X protein (HBx), polynucleotide coding the polypeptide and application of the polypeptide and the polynucleotide. In particular, the invention relates to polypeptide with the functional activity of inhibiting HBx. The polypeptide has the activity of inhibiting HBx at molecular level, cellular level and animal level; therefore, the polypeptide can inhibit hepatitis caused by HBV infection, liver cirrhosis caused by recurrent attacks of hepatitis and liver cancers occurring on the basis of liver cirrhosis. The polypeptide and peptide mimics thereof comprise own functional fragments and functional varieties and genes coding the polypeptide and the peptide mimics or the functional fragments and functional varieties of the polypeptide and the peptide mimics and can be widely used for preventing and treating liver diseases caused by HB infection, including hepatitis, liver cirrhosis and liver cancers.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and / or -8 mediated antiport of sodium and / or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and / or salt present in the GI tract.

The present disclosure concerns methods of administering and detecting a distinguishable agent in a sample from and assessing the condition of an organ in a subject. In a particular embodiment, the present invention concerns methods of detecting and comparing the cholate shunt, in a subject, preferably in a subject with chronic hepatitis C. In certain embodiments, the methods may comprise obtaining a sample from a subject such as a blood or saliva sample after administering an oral and intravenous dose of a distinguishable agent such as cholate and analyzing the sample clearance of the distinguishable agent from the subject and comparing the clearance levels in order to assess hepatic health. In another embodiment, the methods may comprise analyzing a sample from a subject for the presence of a distinguishable agent such as cholate and applying information obtained from analyzing the presence of the distinguishable agent to determine a treatment for a medical condition of the subject.

The invention discloses an application of a mixture containing lactobacillus acidophilus LASW, enterococcus faecium TM39, lactobacillus fermentum LF33 and lactobacillus plantarum BCRC10069 in prevention and / or relieving of alcoholic liver diseases (ALD). The lactobacillus acidophilus LASW, the enterococcus faecium TM39 and the lactobacillus fermentum LF33 are collected in the China Center for Type Culture Collection (CCTCC) with the collection numbers of CCTCC NO:M204083, CCTCC NO:M2012547 and CCTCC NO:M2012548 respectively.

The invention provides a traditional Chinese medicine preparation for treating liver cancer, comprising the following raw medicines in parts by weight: 10-20 parts of acanthopanax, 10-20 parts of oldenlandia diffusa, 10-20 parts of radix astragali, 10-20 parts of cambogia, 10-20 parts of glossy privet fruit, 10-20 parts of white atractylodes rhizome, 10-20 parts of radix polygoni multiflori preparata, 10-20 parts of oriental wormwood, 10-20 parts of turmeric, 10-20 parts of selfheal, 10-20 parts of umbellate pore fungus, 10-20 parts of magnolia vine fruit, 10-20 parts of curcuma zedoary, 10-20 parts of tuckahoe, 10-20 parts of eclipta, 10-20 parts of root of red-rooted salvia, 10-20 parts of white peony root, 10-20 parts of barbed skullcap herb, 10-20 parts of baical skullcap root, 10-20 parts of epimedium, 1-10 parts of toad venom and 1-10 parts of scorpion. The traditional Chinese medicine preparation for treating liver cancer has the beneficial effects of prolonging the life time of inoperable patients, playing an adjuvant treating effect on patients treated mainly by operation, radiation treatment and chemo-treatment, and having certain curative effects on liver cancer-specific backgrounds of liver diseases such as hepatitis and liver cirrhosis.